Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: EZLibra who wrote (3498)	3/20/2000 7:59:00 PM
From: Terry D.	Read Replies (1) \| Respond to of 3702

I didn't even catch that. spokeswoman? Hmmmmm

To: EZLibra who wrote (3498)	3/20/2000 8:14:00 PM
From: AurumRabosa	Read Replies (2) \| Respond to of 3702

I believe she's referring to Oncolym as the MTD trial could proceed rapidly and have them in position to conduct the Phase III efficacy trial in the 2nd quarter: Techniclone said the maximum tolerated dose for the new study will be determined through an 18 patient dose escalation study. Once the maximum dose is discovered, 28 patients will be treated to measure efficacy as part of a Phase II/III study. Subsequent to the treatment of the 28 patients, about 112 patients will be treated as part of the Phase III trial. I thought we dipped down to good technical support so I snagged 5,000 shares today. I'll be watching for any more fortuitous dips to build up a full sized position. The TCLN technology amazes me and I was thinking about how it could be combined with other approaches to treating cancer. I'm also fond of BLSI which is developing a fusion-toxin approach to attacking solid tumor cancers by binding to a receptor that's expressed on the surface of 75% of solid tumors. Cotara would kill from the inside out and BLSI's fusion-toxin could kill from the outside in. TCLN has the VEA technology that can choke off the blood supply to tumors from existing blood vessels. Combine this with BLSI's troponin antiangiogenesis drug which would prevent the growth of new blood vessels and prevent the tumor from growing. I'm sure one could construct such an all encompassing strategy using the drugs from other companies. It may be that due to the speed of action and differences in efficacy that TCLN's drugs would be so fast and so powerful that there's no need to combine them with other drugs from other companies. However, I firmly believe in the benefits of diversifying across companies and technical approaches to curing various diseases.

To: EZLibra who wrote (3498)	3/20/2000 11:16:00 PM
From: GregSL	Read Replies (1) \| Respond to of 3702

"A spokeswoman for Techniclone said on Monday that a Phase III trial will be launched in the second quarter of this year." I think Reuters confused Phase I and Phase III. The study they are referring to is probably the new Phase I Oncolym study. Looking at the quality of the rest of the article, I wouldn't be surprised if Reuters made the mistake here. I doubt that Cotara will be ready for Phase III next quarter. They had only enrolled 9 patients as of last October. Does anybody know the current numbers for the Glioma and Mexico City trials? Still long, Greg